Hemay022+AI

Phase 3Small molecule

TTianjin Hemay Pharmaceutical Co., Ltd

Hemay022+AI is one of 41 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Hemay022+AI

TTianjin Hemay Pharmaceutical Co., Ltd

Phase 3

1 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer

Recruiting·TTianjin Hemay Pharmaceutical Co., Ltd·Phase 3·NCT06313983·339 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hemay022+AI. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hemay022+AI compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hemay022+AI. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tianjin Hemay Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: TTianjin Hemay Pharmaceutical Co., Ltd

Hemay022+AI

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News